This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sahm, D. F.
Right arrow Articles by Thornsberry, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sahm, D. F.
Right arrow Articles by Thornsberry, C.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, September 2000, p. 2521-2524, Vol. 44, No. 9
0066-4804/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.

Analysis of Ciprofloxacin Activity against Streptococcus pneumoniae after 10 Years of Use in the United States

Daniel F. Sahm,1,* Dan E. Peterson,2 Ian A. Critchley,1 and Clyde Thornsberry3

MRL, Herndon, Virginia1; Cereplex, Oakton, Virginia2; and MRL, Franklin, Tennessee3

Received 8 December 1999/Returned for modification 26 March 2000/Accepted 12 June 2000

As the most commonly used fluoroquinolone in the United States since 1987, ciprofloxacin has exerted the greatest selective pressure on S. pneumoniae and provides a valuable marker to evaluate the actual and potential emergence of fluoroquinolone resistance in this species. Analysis of susceptibility results obtained with 5,640 strains collected from throughout the United States showed that only 16 (0.3%) of the isolates demonstrated MICs of >= 4 µg/ml. The prevalence of this phenotype was significantly higher (P < 0.05) among penicillin-resistant populations, among isolates from patients >64 years old, and among respiratory isolates. However, >99% of strains had MICs of <4 µg/ml regardless of the risk group examined, and the MIC population distributions were the same for each risk group. These findings demonstrate that the phenotype of a MIC of >= 4 µg/ml remains uncommon after 10 years of ciprofloxacin use; however, these findings are no reason to become complacent with regard to appropriate use of fluoroquinolones and the need to carefully track resistance trends. Equally important is careful analysis of data that result from surveillance in terms of risk factors and other associated trends so that resistance and susceptibility, and their consequences, are neither over- nor underestimated.

* Corresponding author. Mailing address: MRL Pharmaceutical Services, 13665 Dulles Technology Dr., Suite 200, Herndon, VA 20171. Phone: (703) 480-2500. Fax: (703) 480-2670. E-mail: dsahm{at}thetsn.com.

Antimicrobial Agents and Chemotherapy, September 2000, p. 2521-2524, Vol. 44, No. 9
0066-4804/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Committee on Infectious Diseases, (2006). The Use of Systemic Fluoroquinolones. Pediatrics 118: 1287-1292 [Abstract] [Full Text]  
  • Dias, R., Louro, D., the Antimicrobial Resistance Surveillance Program, , Canica, M. (2006). Antimicrobial Susceptibility of Invasive Streptococcus pneumoniae Isolates in Portugal over an 11-Year Period.. Antimicrob. Agents Chemother. 50: 2098-2105 [Abstract] [Full Text]  
  • Fernandez-Tornero, C., Garcia, E., de Pascual-Teresa, B., Lopez, R., Gimenez-Gallego, G., Romero, A. (2005). Ofloxacin-like Antibiotics Inhibit Pneumococcal Cell Wall-degrading Virulence Factors. J. Biol. Chem. 280: 19948-19957 [Abstract] [Full Text]  
  • Sadowy, E., Izdebski, R., Skoczynska, A., Gniadkowski, M., Hryniewicz, W. (2005). High Genetic Diversity of Ciprofloxacin-Nonsusceptible Isolates of Streptococcus pneumoniae in Poland. Antimicrob. Agents Chemother. 49: 2126-2129 [Abstract] [Full Text]  
  • Powis, J., McGeer, A., Green, K., Vanderkooi, O., Weiss, K., Zhanel, G., Mazzulli, T., Kuhn, M., Church, D., Davidson, R., Forward, K., Hoban, D., Simor, A., Low, D. E. (2004). In Vitro Antimicrobial Susceptibilities of Streptococcus pneumoniae Clinical Isolates Obtained in Canada in 2002. Antimicrob. Agents Chemother. 48: 3305-3311 [Abstract] [Full Text]  
  • Low, D. E., Pichichero, M. E., Schaad, U. B. (2004). Optimizing Antibacterial Therapy for Community-Acquired Respiratory Tract Infections in Children in an Era of Bacterial Resistance. CLIN PEDIATR 43: 135-151 [Abstract]  
  • Schentag, J. J, Meagher, A. K, Forrest, A. (2003). Fluoroquinolone AUIC Break Points and the Link to Bacterial Killing Rates: Part 1: In Vitro and Animal Models. The Annals of Pharmacotherapy 37: 1287-1298 [Abstract] [Full Text]  
  • Hsueh, P.-R., Teng, L.-J., Wu, T.-L., Yang, D., Huang, W.-K., Shyr, J.-M., Chuang, Y.-C., Wan, J.-H., Yan, J.-J., Lu, J.-J., Wu, J.-J., Ko, W.-C., Chang, F.-Y., Yang, Y.-C., Lau, Y.-J., Liu, Y.-C., Lee, C.-M., Leu, H.-S., Liu, C.-Y., Luh, K.-T. (2003). Telithromycin- and Fluoroquinolone-Resistant Streptococcus pneumoniae in Taiwan with High Prevalence of Resistance to Macrolides and {beta}-Lactams: SMART Program 2001 Data. Antimicrob. Agents Chemother. 47: 2145-2151 [Abstract] [Full Text]  
  • Karlowsky, J. A., Thornsberry, C., Critchley, I. A., Jones, M. E., Evangelista, A. T., Noel, G. J., Sahm, D. F. (2003). Susceptibilities to Levofloxacin in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis Clinical Isolates from Children: Results from 2000-2001 and 2001-2002 TRUST Studies in the United States. Antimicrob. Agents Chemother. 47: 1790-1797 [Abstract] [Full Text]  
  • Decousser, J.-W., Pina, P., Picot, F., Delalande, C., Pangon, B., Courvalin, P., Allouch, P., the ColBVH study group, (2003). Frequency of isolation and antimicrobial susceptibility of bacterial pathogens isolated from patients with bloodstream infections: a French prospective national survey. J Antimicrob Chemother 51: 1213-1222 [Abstract] [Full Text]  
  • Jones, M. E., Karlowsky, J. A., Blosser-Middleton, R., Critchley, I. A., Karginova, E., Thornsberry, C., Sahm, D. F. (2002). Longitudinal Assessment of Antipneumococcal Susceptibility in the United States. Antimicrob. Agents Chemother. 46: 2651-2655 [Abstract] [Full Text]  
  • Davidson, R., Cavalcanti, R., Brunton, J. L., Bast, D. J., de Azavedo, J. C.S., Kibsey, P., Fleming, C., Low, D. E. (2002). Resistance to Levofloxacin and Failure of Treatment of Pneumococcal Pneumonia. NEJM 346: 747-750 [Full Text]  
  • Brueggemann, A. B., Coffman, S. L., Rhomberg, P., Huynh, H., Almer, L., Nilius, A., Flamm, R., Doern, G. V. (2002). Fluoroquinolone Resistance in Streptococcus pneumoniae in United States since 1994-1995. Antimicrob. Agents Chemother. 46: 680-688 [Abstract] [Full Text]  
  • Thornsberry, C., Karlowsky, J. A., Sahm, D. F., Jorgensen, J. H., Weigel, L. M., Swenson, J. M., Whitney, C. G., Tenover, F. C., Ferraro, M. J. (2001). Levofloxacin-Resistant Streptococcus pneumoniae: Second Look. Antimicrob. Agents Chemother. 45: 2183-2184 [Full Text]  
  • Karlowsky, J. A., Nealy, L., Sahm, D. F., Thornsberry, C., Jones, M. E., Pfaller, M. A., Jones, R. N. (2001). Trends in Ciprofloxacin Nonsusceptibility and Levofloxacin Resistance among Streptococcus pneumoniae Isolates in North America. J. Clin. Microbiol. 39: 2748-2750 [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»